Renovacor, Inc., a preclinical-stage biopharmaceutical company focusing on developing gene therapy-based treatments for cardiovascular disease, has announced the completion of an $11 million Series A financing. The company’s lead program is a recombinant adeno-associated virus (AAV)-based gene therapy for patients with dilated cardiomyopathy due to mutations in the BAG3 gene. The understanding of BAG3 mutations and the company’s gene therapy product are based on 10 years of research by Arthur M. Feldman, MD, PhD, Laura H. Carnell Professor of Medicine at the Lewis Katz School of Medicine at Temple University. Yahoo! Finance, the Philadelphia Inquirer, the Philadelphia Business Journal, and other media outlets covered the announcement.